CATALENT, INC. (NYSE:CTLT) Files An 8-K Regulation FD Disclosure

Item7.01 Regulation FD Disclosure.

On November 28, 2016, Catalent, Inc. (the Company) issued a press
release announcing that its wholly owned subsidiary, Catalent
Pharma Solutions, Inc. (the Operating Company), has commenced a
private offering (the Private Offering) of $400 million (U.S.
dollar equivalent) aggregate principal amount of euro-denominated
senior unsecured notes due 2024 (the Notes) and intends,
concurrently with the Private Offering, to seek an amendment to
the credit agreement governing its senior secured credit
facilities that would reduce the interest rates applicable to the
term loans thereunder (the Repricing Amendment). The full text of
the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

There can be no assurance that we will be able to complete either
the Private Offering or the Repricing Amendment on terms and
conditions favorable to us or at all, and we may decide to not
pursue either or both of the Private Offering and the Repricing
Amendment before completion.

Portions of the summary section and other information from a
preliminary offering memorandum prepared by the Operating Company
in connection with the Private Offering are attached hereto as
Exhibit 99.2 and are incorporated herein by reference. The
information contained in Exhibit 99.2 should be considered in the
context of the Companys filings with the Securities and Exchange
Commission and other public announcements that the Company may
make by press release or otherwise from time to time. Such
information speaks as of the date of this Current Report on Form
8-K. The Company specifically disclaims any obligation to update
the attached materials in the future, except as may be required
by law.

The information in Item7.01 on this Current Report on Form 8-K
and Exhibits 99.1 and 99.2 attached hereto are being furnished to
the Securities and Exchange Commission to Item7.01 of Form 8-K
and shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section, nor
shall any such information or exhibits be deemed incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended.

The information furnished in this Form 8-K to Item7.01, including
the information contained in Exhibits 99.1 and 99.2, is neither
an offer to sell nor a solicitation of an offer to buy any of the
Notes in the Private Offering.

Item9.01 Financial Statements and Exhibits.

About CATALENT, INC. (NYSE:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

CATALENT, INC. (NYSE:CTLT) Recent Trading Information

CATALENT, INC. (NYSE:CTLT) closed its last trading session down -0.28 at 24.94 with 604,719 shares trading hands.